Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01970696 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

International Ovarian & Testicular Stromal Tumor Registry

Study acronym: OTST
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Publications: 26 to 27v11
  2. Notable Enrollment target: 200 to 300v10 Show 7 more changesShow less
    • Primary completion date: Dec 2025 to Dec 2028
    • Study completion date: Dec 2025 to Dec 2030
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 7 words
    • Collaborators: 10 to 13
    • Publications: 25 to 26
  3. Minor Publications: 26 to 25v9
  4. Notable Primary completion date: Dec 2020 to Dec 2025v8 Show 4 more changesShow less
    • Study completion date: Dec 2025
    • Start date: Dec 2011 to Dec 8, 2011
    • Eligibility criteria shortened, about 8 words
    • Collaborators: 12 to 10
  5. Minor Study description shortened, about 16 words
    • Study site revised
    • Collaborators: 11 to 12
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Re-verified, no change to tracked fieldsv6
  2. Notable Enrollment target: 100 to 200
    • Study description shortened, about 31 words
    • Collaborators: 6 to 11
    • Publications: 22 to 26
    v5
  3. Minor Publications: 8 to 22v4
  4. Notable Primary completion date: Dec 2015 to Dec 2020
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study description expanded, about 1 word
    v3
  5. Minor Publications: 6 to 8v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have recently been found to be associated with a lung cancer of early childhood called pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1 mutations are seen in the majority of children with PPB. Research shows DICER1 mutations are also seen in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly curable when found in early stage; however, later forms of the disease are aggressive and often fatal. The International Ovarian Stromal Tumor Registry collects clinical and biologic data to understand why these tumors occur and how to treat them. Current work involves the study of the role of DICER1 and miRNA expression in ovarian stromal tumors. Understanding the clinical history, predisposing factors and DICER1 and miRNA expression in these ovarian tumors of childhood will lead to targeted screening and risk stratification for evidence-based treatment and biologically rational therapies. These efforts will improve the lives of children by increasing survival and reducing late effects. The specific goals of the International Ovarian and Testicular Stromal Tumor Registry are: 1. to understand risk factors by studying age, pathologic subtype, histopathologic features, tumor invasiveness, degree of differentiation, presence of metastasis 2. to collect information on personal and family history in order to refine the clinical characteristics of patients and families with and without germline DICER1 mutations and other genetic predisposing factors 3. to determine whether there is a pattern of gene expression or DNA alterations that correlate with predisposition to ovarian tumors, biologic behavior and clinical outcome 4. to determine optimal screening regimens 5. to use clinical data obtained through the Registry to refine treatment algorithms 6. to establish a collection of annotated biology specimens (tumor tissue and germline DNA) for future research
Trial Details
NCT Number NCT01970696
Lead Sponsor Children's Hospitals and Clinics of Minnesota
Collaborators: Children's National Research Institute, Dana-Farber Cancer Institute, Washington University School of Medicine, University of Texas Southwestern Medical Center, M.D. Anderson Cancer Center, Children's Hospital Colorado, Rutgers University, Massachusetts General Hospital, Klinikum Dortmund Wirbelsäulenchirurgie, ResourcePath, LLC, Allina Health System, Phoenix Children's Hospital, University of Cambridge
Conditions
(from sponsor)
Ovarian Sex-cord Stromal Tumor, Testicular Stromal Tumors, Ovarian Small Cell Carcinoma
Related terms Sex Cord-Gonadal Stromal Tumors
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov